For pharmaceutical and life sciences companies ready to embrace this moment, the 10 principles aren't a burden. They're a ...
The EMA has backed broader pediatric use of Agamree and Crysvita, lowering age thresholds for rare genetic diseases affecting muscle and bone development.
The EMA has recommended label expansions for Inaqovi, Opdivo, and Venclyxto, broadening treatment options in AML, Hodgkin lymphoma, and CLL.
The European Medicines Agency (EMA) has finalized a document with recommendations on using the European Medicines Regulatory Network (EMRN) Data Quality Framework (DQF) when submitting premarket ...
The PRIME status for RTx-015 was granted based on preliminary Phase I/II safety and efficacy clinical data.
The plan calls for one unit to be ready in 2031 and up to two additional units to come onstream in 2032 Read more at The ...
Matt Goldberg has been an editor with Collider since 2007. As the site's Chief Film Critic, he has authored hundreds of reviews and covered major film festivals including the Toronto International ...